Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes

被引:11
作者
Sohn, Min-Hwan [1 ,2 ,3 ]
Kim, Se Ik [4 ]
Shin, Jong-Yeon [2 ]
Kim, Hee Seung [4 ]
Chung, Hyun Hoon [4 ]
Kim, Jae-Weon [4 ]
Lee, Maria [4 ,5 ]
Seo, Jeong-Sun [1 ,2 ,3 ,6 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Precis Med Ctr, Seongnam Si 13605, South Korea
[2] Macrogen Inc, Precis Med Inst, Seongnam Si 13605, South Korea
[3] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul 03080, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 03080, South Korea
[5] Seoul Natl Univ Hosp, Dept Obstet & Gynecol, Seoul 03080, South Korea
[6] Gong Wu Genom Med Inst, Seongnam Si 13605, South Korea
基金
新加坡国家研究基金会;
关键词
ovarian cancer; high-grade serous carcinoma; gene signature; epithelial-to-mesenchymal transition; homologous recombination repair; DOUBLE-BLIND; CANCER; BREAST; THERAPY; BRCA1;
D O I
10.3390/genes12071103
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
High-grade serous ovarian cancer (HGSOC) is one of the deadliest cancers that can occur in women. This study aimed to investigate the molecular characteristics of HGSOC through integrative analysis of multi-omics data. We used fresh-frozen, chemotherapy-naive primary ovarian cancer tissues and matched blood samples of HGSOC patients and conducted next-generation whole-exome sequencing (WES) and RNA sequencing (RNA-seq). Genomic and transcriptomic profiles were comprehensively compared between patients with germline BRCA1/2 mutations and others with wild-type BRCA1/2. HGSOC samples initially divided into two groups by the presence of germline BRCA1/2 mutations showed mutually exclusive somatic mutation patterns, yet the implementation of high-dimensional analysis of RNA-seq and application of epithelial-to-mesenchymal (EMT) index onto the HGSOC samples revealed that they can be divided into two subtypes; homologous recombination repair (HRR)-activated type and mesenchymal type. Patients with mesenchymal HGSOC, characterized by the activation of the EMT transcriptional program, low genomic alteration and diverse cell-type compositions, exhibited significantly worse overall survival than did those with HRR-activated HGSOC (p = 0.002). In validation with The Cancer Genome Atlas (TCGA) HGSOC data, patients with a high EMT index (>= the median) showed significantly worse overall survival than did those with a low EMT index (<the median) (p = 0.030). In conclusion, through a comprehensive multi-omics approach towards our HGSOC cohorts, two distinctive types of HGSOC (HRR-activated and mesenchymal) were identified. Our novel EMT index seems to be a potential prognostic biomarker for HGSOC.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
    Verhaak, Roel G. W.
    Tamayo, Pablo
    Yang, Ji-Yeon
    Hubbard, Diana
    Zhang, Hailei
    Creighton, Chad J.
    Fereday, Sian
    Lawrence, Michael
    Carter, Scott L.
    Mermel, Craig H.
    Kostic, Aleksandar D.
    Etemadmoghadam, Dariush
    Saksena, Gordon
    Cibulskis, Kristian
    Duraisamy, Sekhar
    Levanon, Keren
    Sougnez, Carrie
    Tsherniak, Aviad
    Gomez, Sebastian
    Onofrio, Robert
    Gabriel, Stacey
    Chin, Lynda
    Zhang, Nianxiang
    Spellman, Paul T.
    Zhang, Yiqun
    Akbani, Rehan
    Hoadley, Katherine A.
    Kahn, Ari
    Koebel, Martin
    Huntsman, David
    Soslow, Robert A.
    Defazio, Anna
    Birrer, Michael J.
    Gray, Joe W.
    Weinstein, John N.
    Bowtell, David D.
    Drapkin, Ronny
    Mesirov, Jill P.
    Getz, Gad
    Levine, Douglas A.
    Meyerson, Matthew
    JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (01) : 517 - 525
  • [32] A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma
    Dong, Fei
    Davineni, Phani K.
    Howitt, Brooke E.
    Beck, Andrew H.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (11) : 1511 - 1516
  • [33] Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
    Zheng Feng
    Di Shao
    Yuhang Cai
    Rui Bi
    Xingzhu Ju
    Dongju Chen
    Chengcheng Song
    Xiaojun Chen
    Jin Li
    Na An
    Yunjin Li
    Qing Zhou
    Zhihui Xiu
    Shida Zhu
    Xiaohua Wu
    Hao Wen
    Journal of Ovarian Research, 16
  • [34] The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma
    Kim, Soyoun Rachel
    Malcolmson, Janet
    Li, Xuan
    Bernardini, Marcus Q.
    Hogen, Liat
    May, Taymaa
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 702 - 706
  • [35] Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing
    Nagasawa, Saya
    Ikeda, Kazuhiro
    Horie-Inoue, Kuniko
    Sato, Sho
    Itakura, Atsuo
    Takeda, Satoru
    Hasegawa, Kosei
    Inoue, Satoshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
  • [36] Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
    Shilpi, Arunima
    Kandpal, Manoj
    Ji, Yanrong
    Seagle, Brandon L.
    Shahabi, Shohreh
    Davuluri, Ramana V.
    JCO CLINICAL CANCER INFORMATICS, 2019, 3 : 1 - 9
  • [37] Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
    Stiegeler, Nadja
    Garsed, Dale W.
    Au-Yeung, George
    Bowtell, David D. L.
    Heinzelmann-Schwarz, Viola
    Zwimpfer, Tibor A.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
    Hatano, Yuichiro
    Fukuda, Shinya
    Makino, Hiroshi
    Tomita, Hiroyuki
    Morishige, Ken-ichirou
    Hara, Akira
    DIAGNOSTIC PATHOLOGY, 2018, 13
  • [39] Prognostic gene expression signature for high-grade serous ovarian cancer
    Millstein, J.
    Budden, T.
    Goode, E. L.
    Anglesio, M. S.
    Talhouk, A.
    Intermaggio, M. P.
    Leong, H. S.
    Chen, S.
    Elatre, W.
    Gilks, B.
    Nazeran, T.
    Volchek, M.
    Bentley, R. C.
    Wang, C.
    Chiu, D. S.
    Kommoss, S.
    Leung, S. C. Y.
    Senz, J.
    Lum, A.
    Chow, V
    Sudderuddin, H.
    Mackenzie, R.
    George, J.
    Fereday, S.
    Hendley, J.
    Traficante, N.
    Steed, H.
    Koziak, J. M.
    Kobel, M.
    McNeish, I. A.
    Goranova, T.
    Ennis, D.
    Macintyre, G.
    De Silva, D. Silva
    Ramon y Cajal, T.
    Garcia-Donas, J.
    Hernando Polo, S.
    Rodriguez, G. C.
    Cushing-Haugen, K. L.
    Harris, H. R.
    Greene, C. S.
    Zelaya, R. A.
    Behrens, S.
    Fortner, R. T.
    Sinn, P.
    Herpel, E.
    Lester, J.
    Lubinski, J.
    Oszurek, O.
    Toloczko, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1240 - 1250
  • [40] Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
    Milanesio, Michela Camilla
    Giordano, Silvia
    Valabrega, Giorgio
    CANCERS, 2020, 12 (05)